BioSpace News Archive

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted inducement stock options to purchase an aggregate of 86,720 shares of its common stock to 5 new employees.

Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results include: For the fourth quarter, total revenues increased 7% to $6.6 billion in comparison to the fourth quarter of 2019

Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million underwritten public offering of its common stock.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced that it intends to offer and sell shares of common stock in an underwritten public offering.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday, February 10, 2021 , after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 10

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced the closing of its previously announced underwritten offering.

Third quarter revenue increases 4% as reported; 1% constant currency organic Third quarter earnings per diluted share increase to $1.33 on a U.S. GAAP basis and $1.73 on an adjusted basis Increased free cash flow driven by net income growth and working capital improvements

The American College of Rheumatology’s (ACR) Rheumatology Research Foundation (RRF) has awarded the Bendcare LLC Columbus Division a research grant to support their project Telehealth-delivered Healthcare to Improve Care (THRIVE) in Community-Practice Rheumatology.

Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 1,923,077 shares of its common stock, at a public offering price of $65.00 per share.